Chemical modification: The key to clinical application of RNA interference?

Journal of Clinical Investigation

Volumn 117, Issue 12, 2007, Pages 3615-3622

  Corey, David R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 2' FLUORO BETA DEXTRO ARABINONUCLEIC ACID; 2' O METHOXY ETHYL PHOSPHOROTHIOATE; 2' O METHYL; ANTISENSE OLIGONUCLEOTIDE; BORANOPHOSPHATE; BORON DERIVATIVE; LOCKED NUCLEIC ACID; MESSENGER RNA; PEGAPTANIB; PHOSPHOROTHIOIC ACID; RIBO DIFLUOROTOLUYL; RIBONUCLEOTIDE; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

CHEMICAL MODIFICATION; CLINICAL TRIAL; DRUG APPROVAL; DRUG CONJUGATION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SPECIFICITY; DRUG STABILITY; DRUG STRUCTURE; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; GENOME; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETINA MACULA DEGENERATION; RETINITIS; REVIEW; RNA BINDING; RNA INTERFERENCE; RNA SEQUENCE; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

GENE EXPRESSION REGULATION; HUMANS; RNA INTERFERENCE; RNA STABILITY; RNA, SMALL INTERFERING;

EID: 36849094017     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33483     Document Type: Review

References (84)

1. Sharp, P.A. 1994. Split genes and RNA splicing. Cell. 77:805-815.
2. Chow, L.T., Gelinas, R.E., Broker, T.R., and Roberts, R.J. 1977. An amazing sequence rearrangement at the 5′ends of adenovirus 2 messenger RNA. Cell. 12:1-8.
3. Altman, S. 1990. Nobel lecture. Enzymatic cleavage of RNA by RNA. Biosci. Rep. 10:317-337.
4. Cech, T.R. 1990. Nobel lecture. Self-splicing and enzymatic activity of an intervening sequence RNA from tetrahymena. Biosci. Rep. 10:239-261.
5. Fire, A., et al. 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391:806-811.
6. Fire, A. 2007. Gene silencing by double-stranded RNA (Nobel lecture). Angew. Chem. Int. Ed. Engl. 46:6966-6984.
7. Mello, C.C. 2007. Return to the RNAi world: Rethinking gene expression and evolution (Nobel Lecture). Angew. Chem. Int. Ed. Engl. 46:6985-6994.
8. Elbashir, S.M., et al. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in mammalian cell culture. Nature. 411:494-498.
9. Janowski, B.A., Hu, J., and Corey, D.R. 2006. Silencing gene expression by targeting chromosomal DNA with antigene peptide nucleic acids and duplex RNAs. Nat. Protoc. 1:436-443.
10. Tiscornia, G., Singer, O., and Verma, I.M. 2006. Design and cloning of lentiviral vectors expressing small interfering RNAs. Nat. Protoc. 1:234-240.
11. Sen, G.L., and Blau, H.M., 2006. A brief history of RNAi: the silence of the genes. FASEB J. 20:1293-1299.
12. Tomari, Y., and Zamore, P.D. 2005. Perspective: machines for RNAi. Genes Dev. 19:517-529.
13. Filipowicz, W. 2005. RNAi: the nuts and bolts of the RISC machine. Cell. 122:17-20.
14. Bumcrot, D., Manoharan, M., Koteliansky, V., and Sah, D.W.Y. 2006. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2:711-719.
15. Corey, D.R. 2007. RNAi learns from antisense. Nat. Chem. Biol. 3:8-11.
16. Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23:3-25.
17. Juliano, R.L., Astriab-Fisher, A., and Falke, D. 2001. Macromolecular therapeutics: Emerging strategies for drug discovery in the postgenome era. Mol. Interv. 1:40-53.
18. Hurko, O. 2006. Understanding the strategic importance of biomarkers for the discovery and early development phases. Drug Discovery World. 7:63-74.
19. Wu, H., et al. 2004. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem. 279:17181-17189.
20. Grillone, L.R., and Lanz, R. 2001. Fomivirsen. Drugs Today. 37:245-255.
21. Ng, E.W., et al. 2006. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug. Discov. 5:123-132.
22. Akdim, F., Stroes, E.S., and Kastelein, J.J. 2007. Antisense apolipoprotein B therapy: where do we stand? Curr. Opin. Lipidol. 18:397-400.
23. Miyake, H., Hara, I., Fujisawa, M., and Gleave, M.E. 2006. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer. Expert Opin. Investig. Drugs. 15:507-517.
24. Liu, G. 2004. Technology evaluation: ISIS-113715, ISIS. Curr. Opin. Mol. Ther. 6:331-336.
25. Geary, R.S., et al. 2006. Lack of pharmacokinetic interaction for ISIS 113715, a 2′-O-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. Clin. Pharmacokinet. 45:789-801.
26. Braasch, D.A., and Corey, D.R. 2002. Novel antisense strategies for controlling gene expression. Biochemistry. 41:4503-4510.
27. Gleave, M.E., and Monia, B.P. 2005. Antisense therapy for cancer. Nat. Rev. Cancer. 5:468-479.
28. Eckstein, F. 2002. Developments in RNA chemistry, a personal view. Biochemie. 84:841-848.
29. Geary, R.S., Yu, R.Z., and Levin, A.A. 2001. Pharmacokinetics of phosphorothioate antisense oligonucleotides. Curr. Opin. Investig. Drugs. 2:562-573.
30. Watanabe, T.A., Geary, R.S., and Levin, A.A. 2006. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides. 16:169-180.
31. Braasch, D.A., et al. 2003. RNA interference in mammalian cells by chemically modified RNA. Biochemistry. 42:7967-7975.
32. Harborth, J., et al. 2003. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. 13:83-105.
33. Chiu, Y., and Rana, T.M. 2003. siRNA function in RNAi: A chemical modification analysis. RNA. 9:1034-1048.
34. Amarzguioui, M., Holen, T., Babaie, E., and Prydz, H. 2003. Tolerance for mutations and chemical modifications in an siRNA. Nucleic Acids Res. 31:589-595.
35. Layzer, J.M., et al. 2004. In vivo activity of nuclease resistant siRNAs. RNA. 10:766-771.
36. Soutschek, J., et al. 2004. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 432:173-178.
37. Morrissey, D.V., et al. 2005. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology. 41:1349-1356.
38. Morrissey, D.V., et al. 2005. Potent and persistent in vivo anti-HBV activity of chemical modified RNAs. Nat. Biotechnol. 23:1002-1007.
39. Kraynack, B.A., and Baker, B.F. 2006. Small interfering RNAs containing full 2′-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity. RNA. 12:163-173.
40. Braasch, D.A., et al. 2004. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg. Med. Chem. Lett. 14:1139-1143.
41. Hall, A.H.S., et al. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res. 32:5991-6000.
42. Hall, A.H.S., et al. High potency silencing by single-stranded boranophosphate siRNA. Nucleic Acids Res. 34:2773-2781.
43. Koshkin, A.A., et al. 1998. LNA (locked nucleic acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine, and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedon. 54:3607-3630.
44. Obika, S., et al. 1998. Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation 2′-O,4′-C-methyleneribonucleotides. Tetrahedron Lett. 39:5401-5404.
45. Braasch, D.A., and Corey, D.R. 2001. Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem. Biol. 8:1-7.
46. Frieden, M., and Orum, H. 2006. The application of locked nucleic acids in the treatment of cancer. IDrugs. 9:706-711.
47. Elmen, J., et al. 2005. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 33:439-447.
48. Mook, O.R., Baas, F., de Wissel, M.B, and Fluiter, K. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol. Cancer Ther. 6:833-843.
49. Swayze, E.E., et al. 2006. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatoxicity. Nucleic Acids Res. 35:687-700.
50. Rusckowski, M., Ou, T., Roskey, A., and Agrawal, S. 2000. Biodistribution and metabolism of a mixed backbone oligonucleotide (GEM 231) following single and multiple dose adminstration in mice. Antisense Nucleic Acid Drug Dev. 10:333-345.
51. Zhang, H., et al. 2000. Reduction of liver Fad expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat. Biotechnol. 18:862-867.
52. Crooke, R.M., et al. 2005. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. 46:872-884.
53. Kawasaki, A.M., et al. 1993. Uniformly modified 2′-deoxy-2′- fluoro phosphorothioate oligonucleotides as nuclease resistant antisense compounds with high affinity and specificity for RNA targets. J. Med. Chem. 36:831-841.
54. Czauderna, F., et al. 2003. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31:2705-2716.
55. Allerson, C.R., et al. 2005. Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem. 48:901-904.
56. Prakash, T.P., et al. 2005. Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J. Med. Chem. 48:4247-4253.
57. Hoshika, S., et al. 2005. RNA interference induced by siRNAs modified with 4′-thioriobnucleosides in cultured mammalian cells. FEBS Lett. 579:3115-3118.
58. Dande, P., et al. 2006. Improving RNA interference in mammalian cells by 4′-Thio-modified small interfering RNA (siRNA): Effect on siRNA activity and nuclease stability when used in combination with 2′-O-alkyl modifications. J. Med. Chem. 49:1624-1634.
59. Koller, E., et al. 2006. Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Res. 34:4467-4476.
60. Jackson, A.L., et al. 2006. Position-specific chemical modifications of siRNAs reduces "off-target" transcription silencing. RNA. 12:1197-1205.
61. Snove, O., and Rossi, J.J. 2006. Chemical modifications rescue off-target effects. ACS Chem. Biol. 1:274-276.
62. Matthias, J., et al. 2007. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNAs pathway. Nature. In press.
63. Dowler, T., et al. 2006. Improvements in siRNA properties mediated by 2′-deoxy-2′-fluoro-S-D-arabinonucleic acid (FANA). Nucleic Acids Res. 34:1669-1675.
64. Watts, J.K., et al. 2007. 2′-Fluoro-4′-thioarabino-modified oligonucleotides: conformational switches linked to siRNA activity. Nucleic Acids Res. 35:1441-1451.
65. Xia, J., et al. 2006. Gene silencing activity of siRNAs with ribo-difluorotoluyl nucleotide. ACS Chem. Biol. 1:176-183.
66. Nielsen, P.G., Egholm, M., Berg, R.H., and Buchardt, O. 1991. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science. 254:1497-1500.
67. Kaihatsu, K., Huffman, K., E., and Corey, D.R. 2004. Intracellular uptake and inhibition of gene expression by PNAs and PNA-peptide conjugates. Biochemistry. 43:14340-14347.
68. Summerton, J. 1999. Morpholino antisense oligomers: the case for an RNAse H-independent structural type. Biochim. Biophys. Acta. 1489:141-158.
69. Muratovska, A., and Eccles, M.R. 2004. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. 558:63-68.
70. Oishi, M., et al. 2005. Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile ?-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J. Am. Chem. Soc. 127:1624-1625.
71. Kim, S.H., et al. 2006. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control. Release. 116:123-129.
72. Kim, W.J., et al. 2006. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol. Ther. 14:343-350.
73. Manoharan, M. 2002. Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action. Antisense Nucleic Acid Drug Dev. 12:103-128.
74. De Paula, D., Bentley, M.V.L.B., and Mahato, R.I. 2007. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA. 13:1-26.
75. McNamara, J.O., et al. 2006. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24:1005-1015.
76. Song, E., et al. 2005. Antibody mediated in vivo delivery of small interfering RNAs via cell surface receptors. Nat. Biotechnol. 23:709-714.
77. Whelan, J. 2005. First clinical data on RNAi. Drug Discov. Today. 15:1014-1015.
78. Fattal, E., and Bochot, A. 2006. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers, and siRNA. Adv. Drug Deliv. Rev. 58:1203-1223.
79. Hadj-Slimane, R., Leppelletier, Y., Lopez, N., Garbay, C., and Raynaud, F. 2007. Short interfering RNA (siRNA), a novel therapeutic tool acting on angiogenesis. Biochemie. 89:1234-1244.
80. Li, B., et al. 2005. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat. Med. 9:944-951.
81. Kumar, P., et al. 2007. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 448:39-43.
82. Zimmerman, T.S., et al. 2006. Nature RNAi-mediated gene silencing in non-human primates. Nature. 441:111-114.
83. Hu-Lieskovan, S., et al. 2005. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral, delivery of small interfering RNA inhibits tumor growth in a murine model of metatstic Ewing's sarcoma. Cancer Res. 65:8984-8992.
84. Landen, C.N., et al. 2005. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65:6910-6918.